• Je něco špatně v tomto záznamu ?

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic

B. Turková, J. Tužil, B. Pilnáčková, H. Doležalová, D. Štrosová, V. Petrů, E. Seberová, T. Doležal

. 2022 ; 14 (14) : 1109-1120. [pub] 20220912

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024279

Grantová podpora
Allergy Therapeutics

Background: The prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. Methods: In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis. Results: Of 471 new AIT users, 317 completed three courses of treatment, and symptoms improved in 96%; no serious adverse reactions were reported. The cost of symptomatic medication decreased by 49% and the cost of unscheduled specialist visits decreased by 73%. Except for AIT administration, total healthcare costs decreased by 54% compared with the baseline pollen season without AIT. Conclusion: In clinical practice, subcutaneous AIT is an effective treatment generating savings on symptomatic medication and unscheduled consultations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024279
003      
CZ-PrNML
005      
20221031100237.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/imt-2022-0143 $2 doi
035    __
$a (PubMed)36097687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Turková, Barbora $u Value Outcomes, Václavská 12, Prague 2, 120 00, Czech Republic $1 https://orcid.org/0000000230755004
245    10
$a Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic / $c B. Turková, J. Tužil, B. Pilnáčková, H. Doležalová, D. Štrosová, V. Petrů, E. Seberová, T. Doležal
520    9_
$a Background: The prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. Methods: In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis. Results: Of 471 new AIT users, 317 completed three courses of treatment, and symptoms improved in 96%; no serious adverse reactions were reported. The cost of symptomatic medication decreased by 49% and the cost of unscheduled specialist visits decreased by 73%. Except for AIT administration, total healthcare costs decreased by 54% compared with the baseline pollen season without AIT. Conclusion: In clinical practice, subcutaneous AIT is an effective treatment generating savings on symptomatic medication and unscheduled consultations.
650    12
$a alergeny $x terapeutické užití $7 D000485
650    _2
$a desenzibilizace imunologická $7 D003888
650    _2
$a lidé $7 D006801
650    12
$a alergie $x terapie $7 D006967
650    _2
$a pyl $7 D011058
650    _2
$a prospektivní studie $7 D011446
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Tužil, Jan $u Value Outcomes, Václavská 12, Prague 2, 120 00, Czech Republic $u First Medical Faculty, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000271824010
700    1_
$a Pilnáčková, Barbora $u Value Outcomes, Václavská 12, Prague 2, 120 00, Czech Republic
700    1_
$a Doležalová, Helena $u Value Outcomes, Václavská 12, Prague 2, 120 00, Czech Republic
700    1_
$a Štrosová, Daniela $u Value Outcomes, Václavská 12, Prague 2, 120 00, Czech Republic
700    1_
$a Petrů, Vít $u Department of allergology & clinical immunology, Synlab Czech s.r.o., Prague, Czech Republic
700    1_
$a Seberová, Ester $u RESPIRAL Ltd., Pilsen, Czech Republic
700    1_
$a Doležal, Tomáš $u Value Outcomes, Václavská 12, Prague 2, 120 00, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 14, č. 14 (2022), s. 1109-1120
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36097687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100235 $b ABA008
999    __
$a ok $b bmc $g 1854161 $s 1175569
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 14 $d 1109-1120 $e 20220912 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
GRA    __
$p Allergy Therapeutics
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace